REG - Revolution Beauty Gp - Press speculation

Revolution BeautyAnnouncement

27/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231127:nRSa6718Ua&default-theme=true

RNS Number : 6718U  Revolution Beauty Group PLC  27 November 2023

27 November 2023

 

Revolution Beauty Group plc

("Revolution Beauty", the "Group" or the "Company")

 

Press speculation

 

Revolution Beauty Group plc (AIM: REVB), the multi-channel mass beauty
innovator, notes the recent press speculation regarding potential agreements
with the Group's former Chief Executive Officer (CEO), Adam Minto, and former
Executive Chairman, Tom Allsworth.

 

As previously announced on 20 June 2023, the Group announced potential legal
proceedings against Mr Minto regarding the events that led to a delay in the
audit of the FY22 results and the suspension of the Company's shares from
trading on AIM.

 

Separately, and as previously announced on 31 August 2023, the Board is
negotiating with Tom Allsworth, the previous owner of Medichem, to reach a
revised agreement on the terms of its acquisition.

 

Revolution Beauty remains in negotiation on both these issues. There is no
guarantee that agreements will be reached. Should agreements be reached, they
would likely be treated as related party transactions and an appropriate
announcement made at that time.

 

For further information please contact:

 

Investor Relations

Lauren Brindley, CEO

Elizabeth Lake, CFO

Investor.Relations@revolutionbeautyplc.com

 

Joint Corporate Brokers

Zeus (NOMAD): Nick Cowles / Jamie Peel / Jordan Warburton

Tel: +44 (0) 161 831 1512

 

Liberum: Dru Danford / Edward Thomas / John More / Miquela Bezuidenhoudt

Tel: +44 (0) 203 100 2222

 

Media enquiries

Headland Consultancy: Matt Denham / Will Smith / Antonia Pollock

Tel: +44 (0)20 3805 4822

Revolutionbeauty@headlandconsultancy.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  SPCZZMZMRVRGFZM